Extension of the subscription period in the ongoing rights issue

Extension of the subscription period in the ongoing rights issue 

The Board of Directors of Tripep AB has resolved, due to the current market
conditions, to extend the subscription period of the ongoing rights issue until
19 September 2008 inclusive. 
The extension does not mean that the period for trading in subscription rights
will be extended. 




For more information, please contact:
Jan Nilsson, CEO, Tripep AB		                         
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63               
E-mail: jan.nilsson@tripep.se		                         

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se


 About Tripep
Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal® and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's website: www.tripep.se.
In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.